hypertriglyceridaemia

News

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.

News

Ionis' Tryngolza claims critical label expansion in US

Ionis' Tryngolza has been approved for severe hypertriglyceridaemia, opening the door to what the company thinks could be a $3bn market opportunity.

News

MSD, Ionis trumpet lipid-lowering drug data

MSD's enlicitide scores in hypercholesterolaemia, as Ionis lines up broader use for recent approval Tryngolza in severe hypertriglyceridaemia.

News

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

News

Ionis, Arrowhead hail data with triglyceride drugs at ACC

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels i

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Ionis' Tryngolza claims critical label expansion in US

MSD, Ionis trumpet lipid-lowering drug data

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Ionis, Arrowhead hail data with triglyceride drugs at ACC

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

hypertriglyceridaemia

Editor's Picks